Association between Uric Acid and Metabolic Syndrome in QazvinMetabolic Diseases Study (QMDS), Iran

Amir Ziaee¹, Neda Esmailzadehha¹, Azam Ghorbani¹ & Saeed Asefzadeh²
¹ Metabolic Diseases Research Center, Qazvin University of Medical Science, Qazvin, Iran
² Research Center for Social Determinants of Health, Qazvin University of Medical Sciences, Qazvin, Iran

Correspondence: Neda Esmailzadehha, General practitioner, Metabolic Diseases Research Center, Booolai-Sina Hospital, Booolai-Sina Street, Qazvin, Iran. Tel: 98-281-336-0084. Fax: 98-281-332-6033. E-mail: nesmailzadehha@qums.ac.ir

Received: October 8, 2012   Accepted: October 15, 2012   Online Published: November 15, 2012
doi:10.5539/gjhs.v5n1p155   URL: http://dx.doi.org/10.5539/gjhs.v5n1p155

Conflict of Interest: Nothing to declare

Abstract

Background: The prevalence of Metabolic Syndrome (MS) has been increasing worldwide. Although Uric Acid (UA) Levels are often increased in subjects with MS, it is still unclear whether uric acid plays a causal role for MS or is a marker. The purpose of this study was to examine the association between UA and the MS in Qazvin, Iran.

Methods: 529 men and 578 women aged 20 – 78 years attended in cross sectional study from September 2010 to April 2011 in Qazvin, Iran. The criteria proposed by new joint Interim societies (JIS) were applied for diagnosis of MS. Hyperuricemia was defined as UA ≥ 7 mg/dL in men and UA ≥ 6 mg/dL in women. Logistic regression analysis was performed to evaluate the relationship between UA quartiles and MS.

Results: The prevalence of MS was found to be 39.3%. Prevalence of hyperuricemia was 8.4% in males and 4.1% in females (P=0.004). Mean UA level was higher in males than in females (P<0.001). UA levels increased significantly with an increasing number of MS components in both genders. Prevalence of MS increased across UA quartiles in females; however the increasing trend began from second quartile in males. Using the lowest quartile of UA level as a reference, there were no significant association between UA quartile groups and MS.

Conclusion: This study showed that UA levels are not an appropriate predictor of MS in Iranian population. More longitudinal studies are necessary to confirm the role of UA in MS occurrence.

Keywords: prevalence, hyperuricemia, logistic regression, association, uric acid

1. Introduction

The metabolic syndrome (MS) refers to a cluster of risk factors, including abdominal obesity, high blood pressure, dyslipidemia and increased plasma glucose (Eckel, Grundy, & Zimmet, 2005). MS is a modern epidemic that is strongly associated with the development of cardiovascular disease and diabetes mellitus (Wilson et al., 2005; Tsouli et al., 2006). The prevalence of MS has been increasing worldwide (Meshkani, Zargari, & Larijani, 2010). In an Iranian study, the prevalence of MS was 30.1% (Azizi et al., 2003). Increasing evidence suggests that uric acid (UA) level may play a role in the MS (Chiou et al., 2010; Nan et al., 2008; Sui et al., 2008).

Large epidemiological studies have established the association of increased serum uric acid levels with MS and its individual components (Lin, Tsai, & Hsu, 2006; Onat et al., 2006; Choi & Ford, 2007; Reimann et al., 2008; Liu, Chang, & Chen, 2010; Saggiani et al., 1996; Bonora et al., 1996; Athyros et al., 2005; Zimmet et al., 1994). Additionally, UA level has been associated with increasing numbers of MS components (Tsouli et al., 2006; Lin, Tsai, & Hsu, 2006; Schmidt et al., 1996). Although UA Levels are often increased in subjects with MS (Yoo et al., 2005; Schmidt et al., 1996), none of the proposed definitions include UA levels in its criteria (Tsouli et al., 2006; Lin, Tsai, & Hsu, 2006; Schmidt et al., 1996).
The prevalence of hyperuricemia has been increased in recent years, in developing countries (Conen et al., 2004). Previous studies demonstrated that increased UA are markers of increased cardiovascular risk independently (Gagliardi, Miname, & Santos, 2009; Montalcini et al., 2007). Given the high prevalence of MS in Iranians, the purpose of this was to examine the association between UA and the MS in Qazvin, Iran.

**2. Methods**

**2.1 Subjects**

This study was a cross sectional population based study that was performed on a representative sample of residents of minoodar district of Qazvin which is located 150 km northwest of Tehran, the capital city of Iran. The ethics committee of Qazvin University of medical sciences approved the study.

All households of the district had health profiles at minoodar health center and the sampling unit was the household. The district was divided into four main clusters with respect to the population size. Inclusion criteria were age ≥ 20 years, owning an apartment in the area and residence for at least next 5 years. People aged ≥ 20 years in every household were selected by multistage cluster random sampling methods. Subjects were invited by phone call to attend the study at the health center and after face to face explanation of the study details, they were free to participate. All subjects gave their written informed consent. 1107 subjects eligible for the study were selected and they were evaluated from September 2010 to April 2011.

**2.2 Data Collection**

Social and demographic data were self-reported in the questionnaire given to the subjects. An organized questionnaire including past medical history, family medical conditions, current medication and physical examination was initially prepared from a literature review. Face and content validity of the questionnaire were reviewed and approved by five experts. Two general practitioners filled out the questionnaires. Anthropometric data were obtained after a 12 – 14 hours overnight fast. Body weight was measured while subjects were lightly clothed to the nearest 0.1 kg using a Seca scale, Germany. Height was measured in a barefoot standing position to an accuracy of 0.5 cm using tape meter while the subjects look straight forward. Body mass index (BMI) was calculated as weight (kg) divided by the height (m) squared. Waist and hip circumference were measured to the nearest 0.1 cm using a flexible, non-elastic measuring tape without any pressure on the tissue. The waist circumference (WC) was measured halfway between the costal margin and the iliac crest at the end of normal expiration. The hip circumference (HC) was considered as the maximal circumference over the great femoral troCHANTERS. Waist-to–hip ratio (WHR) was calculated as WC divided by HC. Blood pressure (BP) was measured three times – on a single occasion – in a seated position using a mercury sphygmomanometer after a 15 min rest. There was an at least 2 minute interval between last two measurements and their average value was registered as subject’s BP. If an abnormal value was obtained, then another measurement was taken after a 30 minute rest.

**2.3 Laboratory Tests**

A venous blood sample of subject was taken after a 12 – 14 hour overnight fast. All the samples were analyzed at the same laboratory on the day of blood collection. Blood levels of glucose, insulin, total cholesterol (Chol), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglycerides (TGs), creatinin (Cr) and uric acid (UA) were measured in all subjects.

A Hitachi 704 auto-analyzer with GOD-PAP method and reagent (Parsazmun Company, Tehran, Iran) was used to measure fasting blood glucose (FBS); Mean intra- and interassay coefficients of variation (CVs) were 1.28 and 0.84, respectively. An oral glucose tolerance test (OGTT) was performed on every subjects who had never been diagnosed with diabetes. Impaired glucose tolerance was defined as a glucose level greater than 140 mg/dL (7.8 mmol/L) but less than 200 mg/dL (11 mmol/L) at two hours. Insulin levels were measured by ELISA using reagent (Monobind Company, USA). A within-run precision CV was 4.9 and total precision CV was 4.9. A Hitachi 704 auto-analyzer with CHOD-PAP and reagent (Parsazmun Company) was used to measure cholesterol; Mean intra- and interassay CVs were 0.61 and 1.22, respectively. A Hitachi 704 auto-analyzer with Immunoturbidimetric and reagent (Parsazmun Company) was used to measure HDL-C and LDL-C; Mean intra- and interassay CVs for HDL-C were 0.73 and 1.8, respectively; for LDL-C they were 0.63 and 1.29, respectively. A Hitachi 704 auto-analyzer with GPO-PAP and reagent (Parsazmun Company) was used to measure TGs; Mean intra- and interassay CVs were 1.82 and 1.04, respectively. A Hitachi 704 auto-analyzer with Uricase and reagent (Parsazmun Company) was used to measure UA; Mean intra- and interassay CVs were 1.18 and 1.13, respectively.
2.4 Definitions

Insulin resistance (IR) was estimated by the homeostatic model assessment (HOMA-IR), as fasting serum insulin (μIU/ml) × fasting plasma glucose (mmol/L) /22.5 (Matthews et al., 1985). Using the last Joint Interim Society criteria, (Alberti et al., 2009) MS was identified when at least three of the following conditions were met: WC ≥ 94 cm in men or ≥ 80 cm in women, serum triglycerides ≥ 150 mg/dl or receiving treatment for hypertriglyceridemia, HDL < 40 mg/dl for men and < 50 mg/dl for women and/or receiving treatment for reduced HDL (e.g. Atorvastatin), Fasting plasma glucose ≥ 100 mg/dl (includes diabetes) and systolic blood pressure (SBP) ≥ 130 mmHg or diastolic blood pressure (DBP) ≥ 85 mmHg and/or receiving treatment for hypertension. Hyperuricemia was defined as UA ≥ 7 mg/dL in men and UA ≥ 6 mg/dL in women (Lu et al., 2012; Gonçalves et al., 2012).

2.5 Data analysis

Kolmogorov Smirnov test was used to examine the normality of variables of interest. Data were recorded as mean plus or minus standard deviation (SD) for normally distributed variables or as median values (minimum – maximum) for non–normally distributed variables. Categorical variables were analyzed by chi square test, T-test was used for analysis of continuous variables and non-normally distributed variables were compared by Mann Whitney U test. The relationship between UA level and other variables including MS components were assessed by Pearson’s correlation coefficients. Logistic regression analysis was performed to evaluate the relationship between UA quartiles and MS. Various variables were considered as the potential confounding factors in five models. P-values less than 0.05 were considered statistically significant.

3. Results

The study was performed for a total of 529 men and 578 women aged 20- 78 years (40.08 ± 10.33). Table 1 presents clinical and biochemical characteristics of the subjects. BMI, WC and WHR were significantly higher in females than in males. Prevalence of the MS was 39.3% of according to the JIS criteria. Overall prevalence of hyperuricemia was 6.2%. Prevalence of hyperuricemia was 8.4% in males and 4.1% in females. (P= 0.004) Mean UA level was higher in males than in females. (P<0.001)

Table 1. Clinical and biochemical characteristics of the study subjects

|                        | Total       | Men          | Women        | p-value   |
|------------------------|-------------|--------------|--------------|-----------|
| Age (year)a            | 40.08 ± 10.33 | 42.31 ± 10.56 | 38.02 ± 9.69 | < 0.001   |
| BMI (kg/m^2)a          | 25.97 ± 4.50  | 25.15 ± 3.71  | 26.73 ± 5   | < 0.001   |
| WC (cm)b               | 89.52 ± 10.57 | 92 ± 9.25     | 87.26 ± 11.18 | < 0.001   |
| WHR                   | 0.846 ± 0.076  | 0.886 ± 0.060  | 0.810 ± 0.071 | < 0.001   |
| SBP (mmHg)b            | 112.35 ± 17.76 | 115.44 ± 17.09 | 109.54 ± 17.90 | < 0.001   |
| DBP (mmHg)a            | 71.59 ± 11.85  | 73.75 ± 11.46  | 69.62 ± 11.87 | < 0.001   |
| Fasting blood glucose (mg/dL)b | 93.5 (73 - 444) | 95 (75.3 - 444) | 92 (73 - 353.3) | < 0.001   |
| 2 hrs Blood glucose (mg/dL)b | 104.1 (60 – 551.5) | 99 (63 – 491) | 107 (60 – 551.5) | < 0.001   |
| Fasting Insulin (μIU/mL)b | 11.1 (0.6 - 135) | 10.9 (1.5 - 135) | 11.3 (0.6 - 87.9) | NS         |
| TGs (mg/dL)b           | 121 (40 - 873)   | 134.5 (41 - 873) | 108.5 (40 - 467) | < 0.001   |
| Total cholesterol (mg/dL)a | 183.29 ± 39.34 | 184.38 ± 39.20 | 182.28 ± 39.48 | NS         |
| HDL-C (mg/dL)b         | 41.1 (15.3 - 85.6) | 37.2 (15.3 - 73.1) | 44.5 (18.4 - 85.6) | < 0.001   |
| LDL-C (mg/dL)b         | 107.06 ± 25.57  | 109.30 ± 24.56  | 104.97 ± 26.32 | 0.005      |
| HOMA-IRb               | 2.58 (0.109 - 35.69) | 2.50 (0.32 - 35.69) | 2.65 (0.109 - 27.65) | NS         |
| Uric acid              | 5.01 ± 1.15     | 5.63 ± 1.05     | 4.44 ± 0.92   | < 0.001    |

aData presented as mean plus or minus standard deviation; bdata presented as median (minimum to maximum); cdata presented as number (percent).

WC: waist circumference; WHR: waist to hip ratio; SBP: systolic blood pressure; DBP: diastolic blood pressure; TGs: triglycerides; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; IR: insulin resistance; NS: not significant
UA levels increased significantly with an increasing number of MS components in both genders (Figure 1). Post Hoc test confirmed that presence of 3 components or more of MS in males, and presence of even one of its components in females led to the above mentioned association.

![Figure 1. Serum uric acid levels according to the number of metabolic syndrome components and sex. Error bars are SDs](image)

Table 2. Comparison of uric acid levels between subjects with and without MS and its features

| MS/Feature | All | Men | Women | P-value |
|------------|-----|-----|-------|---------|
| All        | 5.25±1.12 | 5.84±1.03 | 4.76±0.95 | <0.001 |
| Men        | 4.84±1.11 | 5.47±1 | 4.22±0.83 | <0.001 |
| Women      | 5.47±1 | 5.47±1 | 5.47±1 | <0.001 |
| High BP    | 5.35±1.23 | 5.82±1.22 | 4.72±0.94 | <0.001 |
| All        | 4.90±1.09 | 5.54±0.96 | 4.37±0.90 | <0.001 |
| Men        | 5.54±0.96 | 5.54±0.96 | 5.54±0.96 | 0.006 |
| Women      | 4.37±0.90 | 4.37±0.90 | 4.37±0.90 | <0.001 |
| High WC    | 5.04±1.16 | 5.90±1.10 | 4.60±0.91 | <0.001 |
| All        | 4.98±1.13 | 5.44±0.97 | 4.03±0.79 | <0.001 |
| Men        | 5.44±0.97 | 5.44±0.97 | 5.44±0.97 | <0.001 |
| Women      | 4.03±0.79 | 4.03±0.79 | 4.03±0.79 | <0.001 |
| High FBS   | 5.25±1.19 | 5.69±1.14 | 4.70±1.02 | <0.001 |
| All        | 4.91±1.11 | 5.59±1.00 | 4.35±0.86 | <0.001 |
| Men        | 5.59±1.00 | 5.59±1.00 | 5.59±1.00 | NS |
| Women      | 4.35±0.86 | 4.35±0.86 | 4.35±0.86 | <0.001 |
| High TG    | 5.31±1.13 | 5.79±1.06 | 4.72±0.93 | <0.001 |
| All        | 4.80±1.11 | 5.48±1.03 | 4.29±0.87 | <0.001 |
| Men        | 5.48±1.03 | 5.48±1.03 | 5.48±1.03 | <0.001 |
| Women      | 4.29±0.87 | 4.29±0.87 | 4.29±0.87 | <0.001 |
| Low HDL    | 5.03±1.08 | 5.63±0.95 | 4.55±0.93 | <0.001 |
| All        | 4.97±1.22 | 5.59±1.12 | 4.18±0.81 | NS |
| Men        | 5.59±1.12 | 5.59±1.12 | 5.59±1.12 | NS |
| Women      | 4.18±0.81 | 4.18±0.81 | 4.18±0.81 | <0.001 |

NS: not significant
UA levels of subjects with and without MS and every component of MS has been shown in Table 2. UA levels were significantly higher in subjects with MS, hypertension, central obesity, hypertriglyceridemia, and in females with hyperglycemia and low HDL.

Subjects with hyperuricemia had higher prevalence of every component of MS with the exception of low HDL-C and a 3.23-fold higher risk of MS in comparison with normouricemic subjects. Among the MS components, hypertriglyceridemia demonstrated the strongest association with hyperuricemia (Table 3).

Table 3. Association of hyperuricemia with MS and its features

| UA (mg/L) | M<7, F<6 n= (%) | M≥7, F≥6 n= (%) | OR (95% CI) | P-value |
|-----------|-----------------|-----------------|-------------|---------|
| High WC   | 568(56.3)       | 48(72.7)        | 2.07 (1.18-3.60) | 0.01    |
| High BP   | 250(25)         | 28(41.8)        | 2.16 (1.30-3.58) | 0.004  |
| High TG   | 405(40.1)       | 44(65.7)        | 2.85 (1.69-4.80) | <0.001 |
| High FBS  | 293(29)         | 31(46.3)        | 2.11 (1.28-3.47) | 0.004  |
| Low HDL   | 657(65)         | 47(71.2)        | 1.33 (0.77-2.30) | NS      |
| MS        | 376(37.6)       | 43(66.2)        | 3.23 (1.90-5.49) | <0.001 |

NS: not significant

In both genders, UA levels were positively and significantly correlated with WC, BP and TGs. UA levels were significantly and negatively correlated with HDL-C in females. UA continued to have a significant correlation with WC and TGs level in both genders and with HDL-C in females after adjusting for age, Cr and cholesterol. Otherwise, there was significant and negative correlation between UA levels and FBS in males after this adjustment.

Table 4 shows partial correlations between UA and different variables in 3 models. UA continued to have a significant correlation after adjusting for age and sex, except for diastolic blood pressure (DBP) and FBS. After further adjustment for Cr and cholesterol, there were no significant correlation between UA levels and HOMA-IR. After more adjustment for WC and BMI, UA had positive correlation just with TGs, HDL-C, and 2 hours blood glucose.

Table 4. Partial Correlation coefficients between uric acid and other variables

| Variable                  | Unadjusted | Model 1 | Model 2 | Model 3 |
|---------------------------|------------|---------|---------|---------|
| SBP (mmHg)                | 0.204***   | 0.118   | 0.085   | 0.025   |
| DBP (mmHg)                | 0.158***   | 0.057   | 0.035   | -0.029  |
| BMI (kg/m²)               | 0.166***   | 0.307***| 0.284***| -       |
| WC (Cm)                   | 0.341***   | 0.284***| 0.252***| -       |
| WHR                       | 0.377***   | 0.171***| 0.154***| 0.056   |
| FBS (mg/dl)               | 0.016      | 0.005   | -0.033  | -0.061  |
| 2 hrs Blood glucose (mg/dl)| 0.078**   | 0.119***| 0.099** | 0.065*  |
| Chol (mg/dl)              | 0.232***   | 0.234***| -       | -       |
| TGs (mg/dl)               | 0.357***   | 0.259***| 0.181***| 0.143***|
| HDL-C (mg/dl)             | -0.263***  | -0.109**| -0.144***| -0.092**|
| Fasting Insulin(μU/mL)    | 0.083**    | 0.107** | 0.077*  | 0.017   |
| HOMA-IR                   | 0.077**    | 0.086** | 0.046   | -0.016  |

Model1: Adjusted for age & gender
Model2: Adjusted for age, gender, creatinin & cholesterol
Model3: Adjusted for age, gender, creatinin, cholesterol, BMI & waist circumference

* P-value < 0.05; ** P-value < 0.01; *** P-value < 0.001
The prevalence of MS according to UA quartiles has been shown in Table 5. The quartiles included serum UA levels less than 4.94, 4.94-5.58, 5.58-5.14, and more than 6.14 in males. It considered less than 3.77, 3.77-4.39, 4.39-5.10, and more than 5.10 in females. Prevalence of MS increased across UA quartiles in females; however the increasing trend began from second quartile in males.

Table 5. Prevalence of metabolic syndrome and odds ratio for metabolic syndrome according to the serum uric acid quartile

|                | Q1   | Q2   | Q3   | Q4   |
|----------------|------|------|------|------|
| Whole Subjects (n) | 274  | 263  | 271  | 256  |
| Prevalence n (%)  | 74(27) | 83(31.6) | 115(42.4) | 147(57.4) |
| Unadjusted        | 1    | 0.802(0.553-1.165) | 0.502(0.350-0.719) | 0.274(0.191-0.395) |
| Model 1           | 1    | 1.021(0.877-1.189) | 0.959(0.831-1.107) | 0.890(0.771-1.027) |
| Model 2           | 1    | 0.916(0.771-1.088) | 0.998(0.850-1.172) | 1.052(0.900-1.230) |
| Model 3           | 1    | 1(0.999-1.001) | 1(0.999-1.001) | 1(1-1.001) |
| Model 4           | 1    | 1(0.999-1.001) | 1(0.999-1.001) | 1(0.999-1.001) |
| Model 5           | 1    | 1(1-1.001) | 1(1-1.001) | 1(1-1.001) |

Females Subjects (n) 143 136 144 130
Prevalence n (%) 35(24.5) 48(35.3) 67(46.5) 78(60)
Unadjusted 1 0.594(0.354-0.998) 0.372(0.225-0.616) 0.216(0.129-0.363)
Model 1 1 1.123(0.759-1.664) 0.944(0.654-1.363) 0.826(0.570-1.197)
Model 2 1 0.719(0.453-1.141) 0.946(0.617-1.451) 0.984(0.643-1.506)
Model 3 1 0.999(0.997-1.001) 1(0.998-1.002) 1(0.998-1.002)
Model 4 1 1.002(0.999-1.004) 1(0.998-1.003) 1(0.998-1.003)
Model 5 1 1.001(1-1.002) 1(1-1.002) 1(1-1.003)

Males Subjects (n) 131 127 127 126
Prevalence n (%) 39(29.8) 35(27.6) 48(37.8) 69(54.8)
Unadjusted 1 1.114(0.649-1.912) 0.698(0.415-1.172) 0.350(0.210-0.585)
Model 1 1 0.706(0.473-1.054) 0.653(0.453-0.943) 0.558(0.394-0.790)
Model 2 1 1.316(0.886-1.965) 1.349(0.943-1.931) 1.625(1.164-2.270)
Model 3 1 1.001(0.999-1.003) 1.001(1-1.003) 1.002(1.001-1.004)
Model 4 1 0.999(0.997-1.001) 0.999(0.997-1.001) 0.998(0.997-1.001)
Model 5 1 1(0.999-1.001) 1(0.999-1.002) 1(0.999-1.001)

Model 1: Adjusted for age & gender
Model 2: Adjusted for age & gender & Creatinin
Model 3: Adjusted for age & gender & Cholesterol
Model 4: Adjusted for age & gender & Creatinin & Cholesterol
Model 5: Adjusted for age & gender & Waist Circumference

Using the lowest quartile of UA level as a reference, crude and adjusted multivariate odd's ratios (ORs) were calculated according to various models. Association between UA level quartiles and MS using logistic regression analysis has been shown in Table 5. There were increases in ORs after adjustment for age and gender. After any adjustment for each individual variable in models, the association became insignificant. Cr, Cholesterol and WC were the most important factors in the association; as after adjustment for each of these factors, there were no significant multivariate ORs in both genders. There were no significant association between UA quartile groups and MS.
4. Discussion

Elevated serum UA level is associated with cardiovascular risk factors including hypertriglyceridemia, hypertension, obesity, and hyperglycemia. Presence of these factors together in the same patient is known as MS (Lin, Tsai, & Hsu, 2006). UA levels depend on UA renal excretion and cellular metabolism in the body. Age, gender, genetic factors and dietary habits may influence UA levels (Chiou et al., 2012).

The prevalence of hyperuricemia in the present study was far lower than in many related studies including studies on Iranian population (Sadr et al., 2009; Sari et al.2009; Poletto et al., 2011; Liu et al., 2011; Uaratanawong et al., 2011; Chuang et al., 2011). However, it was similar to a study conducted in Saudi Arabia (Al-Arfaj, 2001). Higher prevalence of hyperuricemia and higher UA levels in males than in females were confirmed in the current study; as they are reported in other comparable studies (Sui et al., 2008; Sadr et al., 2009; Sari et al., 2009; Poletto et al., 2011; Liu et al., 2011; Uaratanawong et al., 2011; Chuang et al., 2011; Al-Arfaj, 2001; Lohsoonthorn, Dhanamun, & Williams et al., 2006; Cai et al., 2009). This finding was not unexpected since it is attributable to the effect of estrogen on UA excretion (Lin, Tsai, & Hsu, 2006). Estrogen therapy in males has been shown to decrease serum UA levels (Nicholls, Snaith, & Scott, 1973).

The present study showed that UA levels were significantly higher in subjects who had increased number of MS components. This relationship was also significant in both genders. These findings have been reported in other studies (Conen et al., 2004; Solymoss et al., 2004; Desai et al., 2005).

UA levels were significantly higher in subjects with the MS compared to healthy individuals. The same relationship is affirmed in other studies (Reimann et al., 2008; Sui et al., 2008; Numata, et al., 2008). Hyperglycemic Females had higher UA levels. It has been shown that UA levels are higher in non-diabetic range of fasting serum glucose level and decreased after the onset of diabetes, particularly in diabetic males (Nan et al., 2008; Lin et al., 2004). Moreover, central obesity, hypertension and hypertriglyceridemia had significant association with hyperuricemia in both genders. Higher UA levels in subjects with central obesity could be mainly explained by impaired renal clearance of uric acid. In addition visceral fat obesity has been strongly associated with excess production of UA (Matsuura et al., 1998).

Although the association of UA and MS is not completely understood, it has been suggested that the relationship between UA levels and MS may be secondary to obesity, insulin resistance, and dyslipidemia (Meshkani, Zargari, & Larijani, 2010). On the other hand it has been proposed that UA may be a causative factor for MS. Hyperinsulinemia increases tubular sodium resorption that results in impaired UA excretion. So, normoglycemic subjects may have higher UA level in the presence of insulin resistance (Facchini et al., 1991). Hyperinsulinemia in subjects with MS decreases renal excretion of UA that contribute to hyperuricemia (Heinig et al., 2006). Insulin resistance is associated with high TGs level, high WC, and low HDL-C (Lin, Tsai, & Hsu, 2006). So, it can be suggested that higher UA levels in subjects with abnormal TGs, HDL-C level and WC may be caused by insulin resistance.

UA levels were positively correlated with WC and TGs level in both genders and were negatively correlated with HDL-C in females in the present study. Unexpectedly negative correlation between UA levels and FBS was found in males that had been also reported by Lu et al formerly (Lu et al., 2012). The Pearson’s correlation coefficient between UA levels and WC was the strongest following TGs level in both genders that suggests the abdominal obesity as a main determinant of hyperuricemia.

We found positive correlation between UA levels and MS and its components including TGs level, BP and WC in studied subjects. Independent correlation of TGs with UA levels has been reported by previous studies; but its underlying biological mechanism has not been elucidated. This association may be due to both environmental and genetic factors (Lin, Tsai, & Hsu, 2006; Fox et al., 1985).

After adjustment for different confounders, there was no significant correlation between UA levels and BP. As WC was a main determinant of UA levels in present study, it may be due to the effect of obesity on SBP and DBP. Negative correlation between UA levels and HDL-C is compatible with studies in Hangzhou and Taiwan (Cai et al., 2009; Chien et al., 2005). The lack of a significant correlation between UA levels, BP and FBS is in agreement with findings of previous studies (Lin, Tsai, & Hsu, 2006; Onat et al., 2006; Yoo et al., 2005; Lim et al., 2010). There are some reports about negative correlation of serum UA with blood glucose levels in diabetic patients; we found similar association for only male subjects in the present study (Tinaahones et al., 2007; Choi & Ford, 2007).

An increase in the prevalence of MS with increasing UA levels was found in the present study that is consistent with previous studies performed on various ethnic groups. These studies have not explained that whether the
The relationship between UA and MS is independent or not (Lin, Tsai, & Hsu, 2006; Onat et al., 2006; Yoo et al., 2005). Positive association between MS severity and UA quartiles has been demonstrated in the present study that is in accordance with Hangzhou study (Cai et al., 2009). Association analysis has been limited to correlation between UA and other variables and comparing the MS prevalence in UA quartiles in most related studies.

The multivariate unadjusted ORs between UA quartiles and MS were less than 1 in the present study which was increased after adjustment for different variables in the models. This is in contrast with findings of Lim et al and Meshkani et al studies in which ORs more than 1 decreased after adjustment (Meshkani, Zargari, & Larijani, 2010; Lim et al., 2010). Low prevalence of hyperuricemia and high prevalence of MS among studied subjects may explain the difference.

When we added Cr, cholesterol levels and WC in adjustment model, the ORs of all quartiles was increased; but the relationship was not statistically significant with regards to confidence interval and P-values. Same results have been reported by the above two mentioned studies. Such results imply that the association between UA levels and MS is not independent, but is affected by various confounders such as physical activity and smoking. In Onat et al study, the ORs of the upper UA tertile were significantly decreased in both genders; but lost significance in males after adjustment for WC (Onat et al., 2006). Three prospective cohort studies in Korea, United States and Portugal have been suggested UA as an independent predictor of MS. They have shown that basal UA levels are associated with higher risk of MS in males and females (Gonçalves et al., 2012; Sui et al., 2008; Ryu et al., 2007). In another study performed in Taiwan the association has been found only in females (Yang et al., 2012).

The present study had some limitations include the cross sectional basis of its design and the number of studied subjects. Some confounders include physical activity; the use of diuretics and a diet habitually high in purines content were not considered. Other unknown confounders may also affect the results.

5. Conclusion

UA level is not a part of JIS criteria or other similar criteria for definition of MS. The association between UA levels and MS is not independent, but is affected by various confounders such as Cr and cholesterol levels, WC, physical activity and smoking. Results of the present study showed that UA levels are not an appropriate predictor of MS in Iranian population. Relatively low prevalence of hyperuricemia, low purine content of Iranian diet and high prevalence of MS may explain these results. More longitudinal studies are necessary to confirm the role of UA in MS occurrence.

Acknowledgement

This study was supported by a grant from the research department of Qazvin University of Medical Sciences. The authors would like to thank the participants involved in this study and the department of research of Qazvin University of Medical Science for endorsing the project. The authors would also like to thank Mrs Zahra Mohammadi and Miss Mahsa khoshpanjeh for their help in preparing this paper.

References

Al-Arfaj, A. S. (2001). Hyperuricemia in Saudi Arabia. Rheumatol Int, 20(2), 61-4. http://dx.doi.org/10.1007/s002960000076

Alberti, K. G., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., ... International Association for the Study of Obesity. (2009). Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention. Circulation, 120(16), 1640-5. http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192644

Athyros, V. G., Ganotakis, E. S., Elisaf, M., & Mikhailidis, D. P. (2005). The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin, 21(8), 1157-9. http://dx.doi.org/10.1185/030079905X53333

Azizi, F., Salehi, P., Etemadi, A., & Zahedi-Asl, S. (2003). Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. Diabetes Res Clin Pract, 61(1), 29-37. http://dx.doi.org/10.1016/S0168-8227(03)00066-4

Bonora, E., Targher, G., Zenere, M. B., Saggiani, F., Cacciatori, V., Tosi, F., ... Mugggeo, M. (1996). Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study. Int J Obes Relat Metab Disord, 20(11), 975-80.

Cai, Z., Xu, X., Wu, X., Zhou, C., & Li, D. (2009). Hyperuricemia and the metabolic syndrome in Hangzhou.
Chien, K. L., Hsu, H. C., Sung, F. C., Su, T. C., Chen, M. F., & Lee, Y. T. (2005). Hyperuricemia as a risk factor on cardiovascular events in Taiwan: The Chin-Shan Community Cardiovascular Cohort Study. *Atherosclerosis, 183*(1), 147-55. http://dx.doi.org/10.1016/j.atherosclerosis.2005.01.018

Chiou, W. K., Huang, D. H., Wang, M. H., Lee, Y. J., & Lin, J. D. (2012). Significance and association of serum uric acid (UA) levels with components of metabolic syndrome (MS in the elderly. *Arch Gerontol Geriatr, 53*(3), 724-8. http://dx.doi.org/10.1016/j.archger.2012.03.004

Chiou, W. K., Wang, M. H., Huang, D. H., Chiu, H. T., Lee, Y. J., & Lin, J. D. (2010). The relationship between serum uric acid level and metabolic syndrome: differences by sex and age in Taiwanese. *J Epidemiol, 20*(3), 219-24. http://dx.doi.org/10.2188/jea.JE20090078

Choi, H. K., & Ford, E. S. (2008). Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels--the Third National Health and Nutrition Examination Survey. *Rheumatology (Oxford), 475*, 713-7. http://dx.doi.org/10.1093/rheumatology/ken066

Choi, H. K., & Ford, E. S. (2007). Prevalence of the metabolic syndrome in individuals with hyperuricemia. *Am J Med, 120*, 442–7. http://dx.doi.org/10.1016/j.amjmed.2006.06.040

Chuang, S. Y., Lee, S. C., Hsieh, Y. T., & Pan, W. H. (2011). Trends in hyperuricemia and gout prevalence: Nutrition and Health Survey in Taiwan from 1993-1996 to 2005-2008. *Asia Pac J Clin Nutr, 20*(2), 301-8.

Conen, D., Wietlisbach, V., Bovet, P., Shamlaye, C., Riesen, W., Paccaud, F., & Burnier, M. (2004). Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. *BMC Public Health, 25*(4), 9. http://dx.doi.org/10.1186/1471-2458-4-9

Desai, M. Y., Santos, R. D., Dalal, D., Carvalho, J. A., Martin, D. R., Flynn, J. A., ... Blumenthal, R. S. (2005). Relation of serum uric acid level with metabolic risk factors in asymptomatic middle-aged Brazilian men. *Am J Cardiol, 95*(7), 865-8. http://dx.doi.org/10.1016/j.amjcard.2004.12.013

Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005). The metabolic syndrome. *Lancet, 365*, 1415–28.

Facchini, F., Chen, Y. D., Hollenbeck, C. B., & Reaven, G. M. (1991). Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. *JAMA, 266*(21), 3008-11. http://dx.doi.org/10.1001/jama.266.21.3008

Fox, I. H., John, D., DeBruyne, S., Dwosh, I., & Marliss, E. B. (1985). Hyperuricemia and hypertriglyceridemia: metabolic basis for the association. *Metabolism, 34*(8), 741-6. http://dx.doi.org/10.1016/0026-0495(85)90025-3

Gagliardi, A. C., Miname, M. H., & Santos, R. D. (2009). Uric acid: A marker of increased cardiovascular risk. *Atherosclerosis, 202*(1), 11-7. http://dx.doi.org/10.1016/j.atherosclerosis.2008.05.022

Gonçalves, J. P., Oliveira, A., Severo, M., Santos, A. C., & Lopes, C. (2012). Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome. *Endocrine, 41*(3), 450-7. http://dx.doi.org/10.1007/s12020-012-9629-8

Heinig, M., & Johnson, R. J. (2006). Role of uric acid in hypertension, renal disease, and metabolic syndrome. *Cleve Clin J Med, 73*(12), 1059-64. http://dx.doi.org/10.3949/ccjm.73.12.1059

Lim, J. H., Kim, Y. K., Kim, Y. S., Na, S. H., Rhee, M. Y., & Lee, M. M. (2010). Relationship between serum uric Acid levels, metabolic syndrome, and arterial stiffness in Korean. *Korean Circ J, 40*(7), 314-20. http://dx.doi.org/10.4070/kcj.2010.40.7.314

Lin, K. C., Tsai, S. T., Lin, H. Y., & Chou, P. (2004). Different progressions of hyperglycemia and diabetes among hyperuricemic men and women in the kinmen study. *J Rheumatol, 31*(6), 1159-65.

Lin, S. D., Tsai, D. H., & Hsu, S. R. (2006). Association between serum uric acid level and components of the metabolic syndrome. *J Chin Med Assoc, 69*(11), 512-6. http://dx.doi.org/10.1016/S1726-4901(09)70320-X

Liu, B., Wang, T., Zhao, Hn., Yue, Ww., Yu, Hp., Liu, Cx., ... Nie, Hw. (2011). The prevalence of hyperuricemia in China: a meta-analysis. *BMC Public Health, 11*, 832. http://dx.doi.org/10.1186/1471-2458-11-832.

Liu, P. W., Chang, T. Y., & Chen, J. D. (2010). Serum uric acid and metabolic syndrome in Taiwanese adults. *Metabolism, 59*, 802–7. http://dx.doi.org/10.1016/j.metabol.2009.09.027

Lohsoonthorn, V., Dhanamun, B., & Williams, M. A. (2006). Prevalence of hyperuricemia and its relationship with metabolic syndrome in Thai adults receiving annual health exams. *Arch Med Res, 37*(7), 883-9.
Lu, W., Song, K., Wang, Y., Zhang, Q., Li, W., Jiao, H., ... Huang, G. (2012). Relationship between serum uric acid and metabolic syndrome: an analysis by structural equation modeling. *J Clin Lipidol, 6*(2), 159-67. http://dx.doi.org/10.1016/j.jacl.2011.11.006

Matsuura F, Yamashita S, Nakamura T, Nishida M, Nozaki S, Funahashi T, & Matsuzawa Y. (1998). Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. *Metabolism, 47*(8), 929-33. http://dx.doi.org/10.1016/S0026-0495(98)90346-8

Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia, 28*(7), 412-9.

Meshkani, R., Zargari, M., & Larijani, B. (2011). The relationship between uric acid and metabolic syndrome in normal glucose tolerance and normal fasting glucose subjects. *Acta Diabetol, 48*(1), 79-88. http://dx.doi.org/10.1007/s00592-010-0231-3

Montalcini, T., Gorgone, G., Gazzaruso, C., Sesti, G., Perticone, F., & Pujia, A. (2007). Relation between serum uric acid and carotid intima-media thickness in healthy postmenopausal women. *Intern Emerg Med, 2*(1), 19-23. http://dx.doi.org/10.1007/s11739-007-0004-3

Nan, H., Qiao, Q., Söderberg, S., Gao, W., Zimmet, P., Shaw, J., ... Tuomilehto, J. (2008). Serum uric acid and components of the metabolic syndrome in non-diabetic populations in Mauritian Indians and Creoles and in Chinese in Qingdao, China. *Metab Syndr Relat Disord, 6*(1), 47-57. http://dx.doi.org/10.1089/met.2007.0028

Nan, H., Qiao, Q., Söderberg, S., Pitkäniemi, J., Zimmet, P., Shaw, J., ... Tuomilehto, J. (2008). Serum uric acid and incident diabetes in Mauritian Indian and Creole populations. *Diabetes Res Clin Pract, 80*(2), 321-7. http://dx.doi.org/10.1016/j.diabres.2008.01.002

Nicholls, A., Snaith, M. L., & Scott, J. T. (1973). Effect of oestrogen therapy on plasma and urinary levels of uric acid. *Br Med J. 1*(5851):449-5. http://dx.doi.org/10.1136/bmj.1.5851.449

Numata, T., Miyatake, N., Wada, J., & Makino, H. (2008). Comparison of serum uric acid levels between Japanese with and without metabolic syndrome. *Diabetes Res Clin Pract, 80*(1), e1-5. http://dx.doi.org/10.1016/j.diabres.2007.10.031

Onat, A., Uyarel, H., Hergenç, G., Karabulut, A., Albayrak, S., Sari, I., ... Keleş, I. (2006). Serum uric acid is a determinant of metabolic syndrome in a population-based study. *Am J Hypertens, 19*(10), 1055-62. http://dx.doi.org/10.1016/j.amjhyper.2006.02.014

Poletto, J., Harima, H. A., Ferreira, S. R., & Gimeno, S. G. (2011). Hyperuricemia and associated factors: a cross-sectional study of Japanese-Brazilians. *Cad Saude Publica, 27*(2), 369-78.

Reimann, M., Schutte, A. E., Malan, L., Huisman, H. W., & Malan, N. T. (2008). Hyperuricaemia is an independent factor for the metabolic syndrome in a sub-Saharan African population: a factor analysis. *Atherosclerosis, 197*, 638–45. http://dx.doi.org/10.1016/j.atherosclerosis.2007.09.011

Ryu, S., Song, J., Choi, B. Y., Lee, S. J., Kim, W. S., Chang, Y., ... Sung, K. C. (2007). Incidence and risk factors for metabolic syndrome in Korean male workers, ages 30 to 39. *Ann Epidemiol, 17*(4), 245-52. http://dx.doi.org/10.1016/j.annepidem.2006.10.001

Sadr, S. M., Namayandeh, S. M., Moadares, M. M., & Rafiei, M. (2009). Serum Uric Acid Levels and Its Association with Cardiovascular Risk Factors. *Iranian J Public Health, 38*(1), 53-59.

Saggiani, F., Pilati, S., Targher, G., Branzi, P., Muggeo, M., & Bonora, E. (1996). Serum uric acid and related factors in 500 hospitalized subjects. *Metabolism, 45*(12), 1557-61. http://dx.doi.org/10.1016/S0026-0495(96)90188-2

Sari, I., Akar, S., Pakoz, B., Sisman, A. R., Gurler, O., Birlik, M., ... Akkoc, N. (2009). Hyperuricemia and its related factors in an urban population, Izmir, Turkey. *Rheumatol Int, 29*(8), 869-74. http://dx.doi.org/10.1007/s00296-008-0806-2

Schmidt, M. I., Duncan, B. B., Watson, R. L., Sharrett, A. R., Brancati, F. L., & Heiss, G. (1996). A metabolic syndrome in whites and African-Americans. The Atherosclerosis Risk in Communities baseline study. *Diabetes Care, 19*(5), 414-8. http://dx.doi.org/10.2337/diacare.19.5.414
Solymoss, B. C., Bourassa, M. G., Campeau, L., Sniderman, A., Marcil, M., Lespérance, J., ... Varga, S. (2004). Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. **Am J Cardiol**, 93(2), 159-64. http://dx.doi.org/10.1016/j.amjcard.2003.09.032

Sui, X., Church, T. S., Meriwether, R. A., Lobelo, F., & Blair, S. N. (2008). Uric acid and the development of metabolic syndrome in women and men. **Metabolism**, 57, 845–852. http://dx.doi.org/10.1016/j.metabol.2008.01.030

Tinahones, F. J., Cardona, F., Rojo-Martínez, G., Almaraz, M. C., Cardona, I., Vázquez-Mellado, J., ... Soriguer, F. (2008). Decreased levels of uric acid after oral glucose challenge is associated with triacylglycerol levels and degree of insulin resistance. **Br J Nutr**, 99(1), 44-8. http://dx.doi.org/10.1017/S0007114507787470

Tsouli, S. G., Liberopoulos, E. N., Mikhailidis, D. P., Athyros, V. G., & Elisaf, M. S. (2006). Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? **Metabolism**, 55(10), 1293-301. http://dx.doi.org/10.1016/j.metabol.2006.05.013

Uaratanawong, S., Suraamornkul, S., Angkeaw, S., & Uaratanawong, R. (2011). Prevalence of hyperuricemia in Bangkok population. **Clin Rheumatol**, 30(7), 887-93. http://dx.doi.org/10.1007/s10067-011-1699-0

Wilson, P. W., D’Agostino, R. B., Parise, H., Sullivan, L., & Meigs, J. B. (2005). Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. **Circulation**, 112, 3066–72. http://dx.doi.org/10.1161/CIRCULATIONAHA.105.539528

Yang, T., Chu, C. H., Bai, C. H., You, S. L., Chou, Y. C., Chou, W. Y., ... Sun, C. A. (2012). Uric acid level as a risk marker for metabolic syndrome: a Chinese cohort study. **Atherosclerosis**, 220(2), 525-31. http://dx.doi.org/10.1016/j.atherosclerosis.2011.11.014

Yoo, T. W., Sung, K. C., Shin, H. S., Kim, B. J., Kim, B. S., Kang, J. H., ... Keum, D. G. (2005). Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. **Circ J**, 69(8), 928-33. http://dx.doi.org/10.1253/circj.69.928

Zimmet, P. Z., Collins, V. R., Dowse, G. K., Alberti, K. G., Tuomilehto, J., Knight, L. T., ... Fareed, D. (1994). Is hyperinsulinaemia a central characteristic of a chronic cardiovascular risk factor clustering syndrome? Mixed findings in Asian Indian, Creole and Chinese Mauritians. Mauritius Noncommunicable Disease Study Group. **Diabet Med**, 11(4), 388-96. http://dx.doi.org/10.1111/j.1464-5491.1994.tb00291.x